Table 2.
Demographic, tumor characteristic and treatment variables of 19,241 women diagnosed with breast cancer between 2005 and 2015 by vital status.
| Vital status | P-value | ||
|---|---|---|---|
| Alive | Dead | ||
| n = 16,083 (84%) | n = 3,158 (16%) | ||
| Median survival time (IQR) | 6.3 (3.8–9.1) | 3.2 (1.7–5.4) | <0.001 |
| Demographics | |||
| Ethnicity | |||
| Chinese | 13,101 (85%) | 2,318 (15%) | <0.001 |
| Malay | 1,588 (75%) | 520 (25%) | |
| Indian | 897 (81%) | 216 (19%) | |
| Other | 497 (83%) | 104 (17%) | |
| Median age (IQR) | |||
| Age group, years | 53 (46–62) | 59 (50–72) | <0.001 |
| <50 | 5,941 (89%) | 758 (11%) | <0.001 |
| 50–69 | 8,566 (85%) | 1,461 (15%) | |
| ≥70 | 1,576 (63%) | 939 (37%) | |
| Year of diagnosis | |||
| 2005–2010 | 8,257 (80%) | 2,115 (20%) | <0.001 |
| 2011–2015 | 7,826 (88%) | 1,043 (12%) | |
| Center | |||
| CGH | 995 (79%) | 258 (21%) | <0.001 |
| KKH | 3,659 (89%) | 455 (11%) | |
| NUH | 2,218 (84%) | 425 (16%) | |
| SGH and NCCS | 7,575 (82%) | 1,609 (18%) | |
| TTSH | 1,636 (80%) | 411 (20%) | |
| Tumor characteristics | |||
| Pre-surgical tumor size | |||
| ≤20 mm | 7,518 (93%) | 608 (7%) | <0.001 |
| 21–50 mm | 4,823 (82%) | 1,074 (18%) | |
| >50 mm | 1,684 (79%) | 444 (21%) | |
| Attached to chest wall | 494 (57%) | 379 (43%) | |
| Unknown | 1,564 (71%) | 653 (29%) | |
| TNM nodal stage | |||
| N0 | 10,628 (92%) | 928 (8%) | <0.001 |
| N1 | 2,823 (83%) | 564 (17%) | |
| N2 | 1,083 (74%) | 383 (26%) | |
| N3 | 623 (60%) | 422 (40%) | |
| Unknown | 926 (52%) | 861 (48%) | |
| Tumor stage | |||
| In situ | 2,734 (95%) | 150 (5%) | <0.001 |
| I | 4,857 (94%) | 326 (6%) | |
| II | 5,464 (87%) | 848 (13%) | |
| III | 1,933 (68%) | 928 (32%) | |
| Unknown | 1,095 (55%) | 906 (45%) | |
| Grade | |||
| Well-differentiated | 2,522 (92%) | 218 (8%) | <0.001 |
| Moderately-differentiated | 5,925 (88%) | 788 (12%) | |
| Poorly-differentiated | 6,397 (80%) | 1,552 (20%) | |
| Unknown | 1,239 (67%) | 600 (33%) | |
| Estrogen receptor status | |||
| Positive | 11,069 (86%) | 1,786 (14%) | <0.001 |
| Negative | 3,275 (77%) | 985 (23%) | |
| Unknown | 1,739 (82%) | 387 (18%) | |
| Progesterone receptor status | |||
| Positive | 9,577 (87%) | 1,484 (13%) | <0.001 |
| Negative | 4,631 (79%) | 1,255 (21%) | |
| Unknown | 1,875 (82%) | 419 (18%) | |
| HER2 status | |||
| Positive | 3,020 (82%) | 675 (18%) | 0.001 |
| Negative | 8,975 (84%) | 1,743 (16%) | |
| Unknown | 4,088 (85%) | 740 (15%) | |
| Proxy subtype | |||
| Luminal A | 5,342 (90%) | 592 (10%) | <0.001 |
| Luminal B, HER2-negative | 2,091 (80%) | 519 (20%) | |
| Luminal B, HER2-positive | 1,810 (83%) | 379 (17%) | |
| HER2-enriched | 1,198 (80%) | 293 (20%) | |
| Basal | 1,217 (73%) | 441 (27%) | |
| Unknown | 4,425 (83%) | 934 (17%) | |
| Treatment | |||
| Surgery | |||
| Yes | 15,295 (87%) | 2,342 (13%) | <0.001 |
| No | 788 (49%) | 816 (51%) | |
| Chemotherapy | |||
| Yes | 6,251 (83%) | 1,301 (17%) | <0.001 |
| No | 2,521 (72%) | 961 (28%) | |
| Not recommended | 7,311 (89%) | 896 (11%) | |
| Radiotherapy | |||
| Yes | 7,013 (87%) | 1,044 (13%) | <0.001 |
| No | 1,180 (73%) | 434 (27%) | |
| Not recommended | 6,243 (91%) | 635 (9%) | |
| Unknown | 1,647 (61%) | 1,045 (39%) | |
| Endocrine therapy | |||
| Yes | 9,217 (86%) | 1,501 (14%) | <0.001 |
| No | 1,305 (85%) | 228 (15%) | |
| Not recommended | 2,843 (77%) | 831 (23%) | |
| Unknown | 2,718 (82%) | 598 (18%) | |
TNM nodal stage: post-surgery if surgery is done.
Tumor stage: post-surgery, patients without surgery are classified as unknown.